Back to Top
World Gastroenterology Organisation
World Gastroenterology Organisation
WGO: Facebook WGO: Twitter

Helicobacter Pylori in Developing Countries

Level: Meta-analyses, Systematic reviews, Practice guidelines: 70 Abstracts

Legend: : Key Development,  : Very Important,  : Important, [no star]: Special Mention


Virological response to entecavir is associated with a better clinical outcome inchronic hepatitis B patients with cirrhosis.
Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, HofmannWP, Petersen J, Fasano M, Buti M, Berg T, Hansen BE, Sonneveld MJ, Wedemeyer H,Janssen HL; VIRGIL Surveillance Study Group., Gut. 2013 May;62(5):760-5. doi: 10.1136/gutjnl-2012-302024. Epub 2012 Apr 5.

Comments: Virological response (VR) defined as HBV DNA <80 IU/ml. obtained by Entecavir is associated with less disease progression in pts with cirrhosis. However, no difference in disease progression was seen between the by-treatment- obtained VR and the natural viremia of < 2000 IU/ml.


Regression of cirrhosis during treatment with tenofovir disoproxil fumarate forchronic hepatitis B: a 5-year open-label follow-up study.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK,Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ., Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1. Epub2012 Dec 10.


Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review.
Ito M, Takata S, Tatsugami M, Wada Y, Imagawa S, Matsumoto Y, Takamura A, Kitamura S, Matsuo T, Tanaka S, Haruma K, Chayama K, J Gastroenterol. 2009;44(5):365-71

Eradication therapy for Helicobacter pylori.
N Vakil, F Megraud, Gastroenterology. 2007 Sep:985-1001

Host-bacterial interactions in Helicobacter pylori infection.
MR Amieva, EM El-Omar, Gastroenterology. 2008 Jan:306-23


Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y(1), Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P., Cochrane Database Syst Rev. 2013 Dec 11;12:CD008337. doi:10.1002/14651858.CD008337.pub2.

Comments: Increasing the duration of PPI-based triple therapy increases H. pylori eradication rates. The optimal duration seems to be for PCA (PPI + clarithromycin + amoxicillin) and for PAN (PPI + amoxicillin + nitroimidazole) 14 days.


Scheduled endoscopic surveillance controls secondary cancer after curativeendoscopic resection for early gastric cancer: a multicentre retrospective cohortstudy by Osaka University ESD study group.
Kato M(1), Nishida T, Yamamoto K, Hayashi S, Kitamura S, Yabuta T, Yoshio T, Nakamura T, Komori M, Kawai N, Nishihara A, Nakanishi F, Nakahara M, Ogiyama H, Kinoshita K, Yamada T, Iijima H, Tsujii M, Takehara T., Gut. 2013 Oct;62(10):1425-32. doi: 10.1136/gutjnl-2011-301647. Epub 2012 Aug 21.

Comments: Synchronous or metachronous multiple early gastric CA were detected in 13.9% of 175 pts during 26.8 mths; 19% of synchronous cancers were not detected until the initial endoscopic submucosal dissection.


The benefit of mass eradication of Helicobacter pylori infection: acommunity-based study of gastric cancer prevention.
Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, Wu MS, Lin JT., Gut. 2013 May;62(5):676-82. doi: 10.1136/gutjnl-2012-302240. Epub 2012 Jun 14.

Comments: Eradication of H pylori infection has led to a reduction in gastric atrophy at the expense of increased oesophagitis. It is not yet clear whether this will lead to a reduction in gastric cancer


Helicobacter pylori resistance to antibiotics in Europe and its relationship toantibiotic consumption.
Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP,Goossens H, Glupczynski Y; Study Group participants., Gut. 2013 Jan;62(1):34-42. doi: 10.1136/gutjnl-2012-302254. Epub 2012 May 12.


Second cancers and residual disease in patients treated for gastricmucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication andfollowed for 10 years.
Wündisch T, Dieckhoff P, Greene B, Thiede C, Wilhelm C, Stolte M, Neubauer A., Gastroenterology. 2012 Oct;143(4):936-42; quiz e13-4. doi:10.1053/j.gastro.2012.06.035. Epub 2012 Jun 27.


Association between nucleoside analogues and risk of hepatitis B virus�relatedhepatocellular carcinoma recurrence following liver resection.
Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT., JAMA. 2012 Nov 14;308(18):1906-14.


Randomized, placebo-controlled trial of tenofovir disoproxil fumarate inadolescents with chronic hepatitis B.
Murray KF, Szenborn L, Wysocki J, Rossi S, Corsa AC, Dinh P, McHutchison J, Pang PS, Luminos LM, Pawlowska M, Mizerski J., Hepatology. 2012 Dec;56(6):2018-26. doi: 10.1002/hep.25818. Epub 2012 Aug 27.


A multicenter validation of an endoscopic classification with narrow band imagingfor gastric precancerous and cancerous lesions.
Pimentel-Nunes P, Dinis-Ribeiro M, Soares JB, Marcos-Pinto R, Santos C, RolandaC, Bastos RP, Areia M, Afonso L, Bergman J, Sharma P, Gotoda T, Henrique R,Moreira-Dias L., Endoscopy. 2012 Mar;44(3):236-46. doi: 10.1055/s-0031-1291537. Epub 2012 Jan 31.

Comments: An endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions: regular vessels with circular mucosa" ( A) = normal histology (accuracy 83%); "tubulo-villous mucosa" (B) = intestinal metaplasia (accuracy 84%) and "irregular vessels and mucosa" (C) = dysplasia (accuracy 95%).


Management of precancerous conditions and lesions in the stomach (MAPS):guideline from the European Society of Gastrointestinal Endoscopy (ESGE),European Helicobacter Study Group (EHSG), European Society of Pathology (ESP),and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).
Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M,O'Connor A, Pereira C, Pimentel-Nunes P, Correia R, Ensari A, Dumonceau JM,Machado JC, Macedo G, Malfertheiner P, Matysiak-Budnik T, Megraud F, Miki K,O'Morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ;European Society of Gastrointestinal Endoscopy; European Helicobacter StudyGroup; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva., Endoscopy. 2012 Jan;44(1):74-94. doi: 10.1055/s-0031-1291491. Epub 2011 Dec 23.

Comments: ESGE recommendations emphasize the increased cancer risk in patients with gastric atrophy and metaplasia, and the need for adequate staging in high grade dysplasia, and focus on treatment and surveillance indications and methods.


Effects of selective COX-2 inhibitor and Helicobacter pylori eradication onprecancerous gastric lesions.
Wong BC, Zhang L, Ma JL, Pan KF, Li JY, Shen L, Liu WD, Feng GS, Zhang XD, Li J, Lu AP, Xia HH, Lam S, You WC., Gut. 2012 Jun;61(6):812-8. doi: 10.1136/gutjnl-2011-300154. Epub 2011 Sep 13.

Comments: Helicobacter pylori and overexpression of COX-2 are associated with gastric cancer. To evaluate the effect of a selective COX-2 inhibitor alone and combined with H pylori eradication on the evolution of precancerous gastric lesions, A randomised, placebo-controlled trial in Linqu County, China, showed that.celecoxib treatment or H pylori eradication had beneficial effects on the regression of advanced gastric lesions


Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D, Am J Gastroenterol. 2009 Dec;104(12):3069-79; quiz 1080


Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection.
Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA, Second Asia-Pacific Conference, J Gastroenterol Hepatol. 2009 Oct;24(10):1587-600


Guidelines for prevention of NSAID-related ulcer complications.
Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology, Am J Gastroenterol. 2009 Mar;104(3):728-38


Carcinogenesis of Helicobacter pylori.
P Correa, J Houghton, Gastroenterology. 2007 Aug:659-72


Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles.
G Emilia, M Luppi, P Zucchini, M Morselli, L Potenza, F Forghieri, F Volzone, G Jovic, G Leonardi, A Donelli, G Torelli, Blood. 2007 Dec 1:3833-41


Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies.
KT Wilson, JE Crabtree, Gastroenterology. 2007 Jul:288-308


Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a lar
W Fischbach, ME Goebeler, A Ruskone-Fourmestraux, T Wundisch, A Neubauer, M Raderer, A Savio, EGILS (European Gastro-Intestinal Lymphoma Study) Group, Gut. 2007 Dec:1685-7


The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis.
A Zullo, V De Francesco, C Hassan, S Morini, D Vaira, Gut. 2007 Oct:1353-7


Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis.
Li BZ, Threapleton DE, Wang JY, Xu JM, Yuan JQ, Zhang C, Li P, Ye QL, Guo B, Mao C, Ye DQ., BMJ. 2015 Aug 19;351:h4052. doi: 10.1136/bmj.h4052. Review.

The problem of Helicobacter pylori resistance to antibiotics: a systematic reviewin Latin America.
Camargo MC(1), García A(2), Riquelme A(3), Otero W(4), Camargo CA(5),Hernandez-García T(2), Candia R(3), Bruce MG(6), Rabkin CS(1)., Am J Gastroenterol. 2014 Apr;109(4):485-95. doi: 10.1038/ajg.2014.24. Epub 2014Mar 4.

Comments: Resistance to first-line anti-H. pylori AB (incl clarithromycin) is high in Latin America.

Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice.
McNicholl AG(1), Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, CalvetX, de la Coba C, Montoro M, Bory F, Perez-Aisa A, Forné M, Gisbert JP;Participant Centres., Gut. 2014 Feb;63(2):244-9. doi: 10.1136/gutjnl-2013-304820. Epub 2013 May 11.

Comments: Prospective RCT in 11 Spanish hospitals: randomisation to sequential or concomitant treatment (amoxicillin, clarithromycin and metronidazole): concomitant therapy led to a non-statistically significant advantage (5%) over sequential therapy (close to 90% cure rates).

Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy.
Gatta L(1), Vakil N, Vaira D, Scarpignato C., BMJ. 2013 Aug 7;347:f4587. doi: 10.1136/bmj.f4587.

Comments: Eradication rates with pre-existing and new therapies for H. pylori are suboptimal.


Identification of genetic loci associated with Helicobacter pylori serologicstatus.
Mayerle J, den Hoed CM, Schurmann C, Stolk L, Homuth G, Peters MJ, Capelle LG,Zimmermann K, Rivadeneira F, Gruska S, Völzke H, de Vries AC, Völker U, Teumer A,van Meurs JB, Steinmetz I, Nauck M, Ernst F, Weiss FU, Hofman A, Zenker M,Kroemer HK, Prokisch H, Uitterlinden AG, Lerch MM, Kuipers EJ., JAMA. 2013 May 8;309(18):1912-20. doi: 10.1001/jama.2013.4350.

Comments: GWAS meta-analysis identified an association between TLR1 and H. pylori seroprevalence, but confirmation in other populations is required and functional interpretation


Gastro-oesophageal reflux disease.
Bredenoord AJ, Pandolfino JE, Smout AJ., Lancet. 2013 Jun 1;381(9881):1933-42. doi: 10.1016/S0140-6736(12)62171-0. Epub2013 Mar 8.


Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, BravoLE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC, Meza-Montenegro MM, Peña EM,Peña R, Correa P, Martínez ME, Chey WD, Valdivieso M, Anderson GL, Goodman GE,Crowley JJ, Baker LH., JAMA. 2013 Feb 13;309(6):578-86. doi: 10.1001/jama.2013.311.


Sequential versus triple therapy for the first-line treatment of Helicobacterpylori: a multicentre, open-label, randomised trial.
Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC,Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS; Taiwan Helicobacter Consortium., Lancet. 2013 Jan 19;381(9862):205-13. doi: 10.1016/S0140-6736(12)61579-7. Epub2012 Nov 16.


Gastroprotective therapy does not improve outcomes of patients with Helicobacter pylori-negative idiopathic bleeding ulcers.
Wong GL, Au KW, Lo AO, Tse YK, Ching JY, To KF, Chan FK., Clin Gastroenterol Hepatol. 2012 Oct;10(10):1124-9. doi:10.1016/j.cgh.2012.06.012. Epub 2012 Jun 23.


Efficacy of hepatitis B vaccination and revaccination and factors impacting onresponse in patients with inflammatory bowel disease.
Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M., Am J Gastroenterol. 2012 Oct;107(10):1460-6. doi: 10.1038/ajg.2012.79.


Randomised study comparing 48 and 96 weeks peginterferon a-2a therapy in genotypeD HBeAg-negative chronic hepatitis B.
Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V,Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B,Facchetti F, Colombo M; PegBeLiver Study Group., Gut. 2013 Feb;62(2):290-8. doi: 10.1136/gutjnl-2011-301430. Epub 2012 Aug 2.


Meta-analysis: the effects of Saccharomyces boulardii supplementation onHelicobacter pylori eradication rates and side effects during treatment.
Szajewska H, Horvath A, Piwowarczyk A., Aliment Pharmacol Ther. 2010 Nov;32(9):1069-79. doi:10.1111/j.1365-2036.2010.04457.x. Epub 2010 Sep 16.


Systematic review: Helicobacter pylori and the risk of upper gastrointestinalbleeding risk in patients taking aspirin.
Fletcher EH, Johnston DE, Fisher CR, Koerner RJ, Newton JL, Gray CS., Aliment Pharmacol Ther. 2010 Oct;32(7):831-9. doi:10.1111/j.1365-2036.2010.04415.x.


Association between Helicobacter pylori infection and inflammatory bowel disease:a meta-analysis and systematic review of the literature.
Luther J, Dave M, Higgins PD, Kao JY., Inflamm Bowel Dis. 2010 Jun;16(6):1077-84.


Association between Helicobacter pylori infection and inflammatory bowel disease: A meta-analysis and systematic review of the literature.
Luther J, Dave M, Higgins PD, Kao JY, Inflamm Bowel Dis. 2009 Sep 16;


Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD, Am J Gastroenterol. 2010 Jan;105(1):65-73


Review article: Helicobacter pylori-negative duodenal ulcer disease.
Gisbert JP, Calvet X, Aliment Pharmacol Ther. 2009 Oct 15;30(8):791-815


Altered gastric corpus expression of tissue inhibitors of metalloproteinases in human and murine Helicobacter infection.
K Bodger, S Ahmed, L Pazmany, DM Pritchard, A Micheal, AL Khan, R Dimaline, GJ Dockray, A Varro, J Clin Pathol. 2008 Jan:72-8


Breath tests for gastrointestinal disease: the real deal or just a lot of hot air?
RJ Saad, WD Chey, Gastroenterology. 2007 Dec:1763-6


Detection of Helicobacter pylori gastritis by PCR: correlation with inflammation scores and immunohistochemical and CLOtest findings.
J Weiss, TK Tsang, X Meng, H Zhang, E Kilner, E Wang, W Watkin, Am J Clin Pathol. 2008 Jan:89-96


Helicobacter pylori gastritis in children is associated with a regulatory T-cell response.
PR Harris, SW Wright, C Serrano, F Riera, I Duarte, J Torres, A Peña, A Rollán, P Viviani, E Guiraldes, JM Schmitz, RG Lorenz, L Novak, LE Smythies, PD Smith, Gastroenterology. 2008 Feb:491-9


Helicobacter pylori infection induces candidate stem cell marker Musashi-1 in the human gastric epithelium.
H Murata, S Tsuji, M Tsujii, T Nakamura, HY Fu, H Eguchi, K Asahi, H Okano, S Kawano, N Hayashi, Dig Dis Sci. 2008 Feb:363-9


Helicobacter pylori vaccine: from past to future.
K Agarwal, S Agarwal, Mayo Clin Proc. 2008 Feb:169-75


Immunochromatographic monoclonal test for detection of Helicobacter pylori antigen in stool is useful in children from high-prevalence developing country.
J Nares-Cisneros, Y Jaramillo-Rodríguez, VA Martínez-Ordaz, VM Velasco-Rodríguez, A Madero, G Mena-Arias, L Manriquez-Covarrubias, Helicobacter. 2007 Aug:354-8


Serum and tissue beta-2 microglobulin levels in patients with Helicobacter pylori infection.
H Akay, A Akay, S K&oeig;klu, Dig Dis Sci. 2008 Feb:358-62


Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pyloriinfection: Systematic review and meta-analysis of efficacy and tolerability.
Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD., Am J Gastroenterol. 2010 Jan;105(1):65-73. Epub 2009 Sep 15.


Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy.
Zou J, Dong J, Yu XF, Helicobacter. 2009 Apr;14(2):119-27


Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication.
Essa AS, Kramer JR, Graham DY, Treiber G, Helicobacter. 2009 Apr;14(2):109-18


Helicobacter pylori infection and iron stores: a systematic review and meta-analysis.
Muhsen K, Cohen D, Helicobacter. 2008 Oct;13(5):323-40


Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication.
Sachdeva A, Nagpal J, Aliment Pharmacol Ther. 2009 Apr 1;29(7):720-30


Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis.
Wang C, Yuan Y, Hunt RH, Am J Gastroenterol. 2009 Feb;104(2):492-500; quiz 491, 501


Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G, Helicobacter. 2008 Dec;13(6):532-41


Systematic review: Helicobacter pylori infection and impaired drug absorption.
Lahner E, Annibale B, Delle Fave G, Aliment Pharmacol Ther. 2009 Feb 15;29(4):379-86


Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials.
Sachdeva A, Nagpal J, Eur J Gastroenterol Hepatol. 2009 Jan;21(1):45-53


13C-urea breath test values and Helicobacter pylori eradication.
A Zullo, F Perna, C Ricci, C Hassan, A Tampieri, V De Francesco, S Morini, D Vaira, Dig Dis Sci. 2008 Feb:370-4


Childhood Helicobacter pylori infection and growth impairment in developing countries: a vicious cycle?
HJ Windle, D Kelleher, JE Crabtree, Pediatrics. 2007 Mar:e754-9


Asia-Pacific consensus guidelines on gastric cancer prevention.
F Di Mario, LG Cavallaro, C Scarpignato, J Gastroenterol Hepatol. 2008 Mar;23(3):351-65


Comparison of biopsy-based methods for the detection of Helicobacter pylori infection.
J Yakoob, S Abid, W Jafri, Z Abbas, M Islam, Z Ahmad, Br J Biomed Sci. 2006:159-62


Critical role of Helicobacter pylori in the pattern of gastritis and carditis in residents of an area with high prevalence of gastric cardia cancer.
M Sotoudeh, MH Derakhshan, B Abedi-Ardakani, M Nouraie, A Yazdanbod, SM Tavangar, J Mikaeli, S Merat, R Malekzadeh, Dig Dis Sci. 2008 Jan:27-33


Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication.
L Fuccio, ME Minardi, RM Zagari, D Grilli, N Magrini, F Bazzoli, Ann Intern Med. 2007 Oct 16:553-62


Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy.
JL Tong, ZH Ran, J Shen, CX Zhang, SD Xiao, Aliment Pharmacol Ther. 2007 Jan 15:155-68


Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment.
Jafri NS, Hornung CA, Howden CW, Ann Intern Med. 2008 Jun 17;148(12):923-31


Regulation of IL-18 in Helicobacter pylori infection.
K Yamauchi, IJ Choi, H Lu, H Ogiwara, DY Graham, Y Yamaoka, J Immunol. 2008 Jan 15:1207-16


Relationship among oxidative DNA damage, gastric mucosal density and the relevance of cagA, vacA and iceA genotypes of Helicobacter pylori.
MS Ladeira, RC Bueno, BF Dos Santos, CL Pinto, RP Prado, MG Silveira, MA Rodrigues, W Bartchewsky Jr, J Pedrazzoli Jr, ML Ribeiro, DM Salvadori, Dig Dis Sci. 2008 Jan:248-55


Seroprevalence of Helicobacter pylori infection in Malaysian children: evidence for ethnic differences in childhood.
CC Boey, KL Goh, WS Lee, N Parasakthi, J Paediatr Child Health. 1999 Apr:151-2


Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection.
T Suzuki, K Matsuo, A Sawaki, H Ito, K Hirose, K Wakai, S Sato, T Nakamura, K Yamao, R Ueda, K Tajima, Aliment Pharmacol Ther. 2006 Jul 15:273-80


Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori?
M Gotteland, O Brunser, S Cruchet, Aliment Pharmacol Ther. 2006 Apr 15:1077-86


The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
S Padol, Y Yuan, M Thabane, IT Padol, RH Hunt, Am J Gastroenterol. 2006 Jul:1467-75